The present application relates to a medicine for treating tumors. A novel attenuated oncolytic virus strain is provided by means of a site-directed mutation of a wild-type virus matrix protein M of a vesicular stomatitis virus. On the basis of the attenuated oncolytic virus strain, an oncolytic virus vaccine is provided by inserting an exogenous gene into the attenuated strain. A medicine capable of treating multiple types of tumors is provided by the use of the oncolytic virus vaccine in combination with the immune checkpoint inhibitor.

The present application relates to a medicine for treating tumors. A novel attenuated oncolytic virus strain is provided by means of a site-directed mutation of a wild-type virus matrix protein M of a vesicular stomatitis virus. On the basis of the attenuated oncolytic virus strain, an oncolytic virus vaccine is provided by inserting an exogenous gene into the attenuated strain. A medicine capable of treating multiple types of tumors is provided by the use of the oncolytic virus vaccine in combination with the immune checkpoint inhibitor.

A vaccination method is provided. The method comprises administering to a mammal a histone deacytelase inhibitor in conjunction with a vaccine that expresses an antigen to which the mammal has a pre-existing immunity.

A vaccination method is provided. The method comprises administering to a mammal a histone deacytelase inhibitor in conjunction with a vaccine that expresses an antigen to which the mammal has a pre-existing immunity.

The present invention includes methods and compositions for enhancing the efficacy of SMCs in the treatment of cancer. In particular, the present invention includes methods and compositions for combination therapies that include an SMC and at least a second agent that stimulates one or more apoptotic or immune pathways. The second agent may be, e.g., an immunostimulatory compound or oncolytic virus.

The present invention includes methods and compositions for enhancing the efficacy of SMCs in the treatment of cancer. In particular, the present invention includes methods and compositions for combination therapies that include an SMC and at least a second agent that stimulates one or more apoptotic or immune pathways. The second agent may be, e.g., an immunostimulatory compound or oncolytic virus.

Provided herein is a method for inducing an immune response to at least one neoantigen, the method comprising administering to a subject a priming composition comprising a peptide antigen conjugate and at least a first boost. The first boost comprises a first oncolytic virus comprising a genome that expresses a first peptide or a second peptide, wherein the first and second peptide are each capable of inducing an immune response to at least one neoantigen. The method further comprises administering the subject a second boost, comprising a second oncolytic virus comprising a genome that expresses a third peptide or a fourth peptide, wherein the third peptide and the fourth peptide are each capable of inducing an immune response to at least one neoantigen, and wherein the second oncolytic virus is immunologically distinct from the first oncolytic virus. The subject may have pre-existing immunity to the at least one neoantigen.

Provided herein is a method for inducing an immune response to at least one neoantigen, the method comprising administering to a subject a priming composition comprising a peptide antigen conjugate and at least a first boost. The first boost comprises a first oncolytic virus comprising a genome that expresses a first peptide or a second peptide, wherein the first and second peptide are each capable of inducing an immune response to at least one neoantigen. The method further comprises administering the subject a second boost, comprising a second oncolytic virus comprising a genome that expresses a third peptide or a fourth peptide, wherein the third peptide and the fourth peptide are each capable of inducing an immune response to at least one neoantigen, and wherein the second oncolytic virus is immunologically distinct from the first oncolytic virus. The subject may have pre-existing immunity to the at least one neoantigen.

Disclosed herein are methods of treating cancer by administering a heterologous prime-boost regimen of oncolytic microorganisms that enhances or elicits an immune response to a tumor protein that is not coded for by the oncolytic microorganisms.

Some embodiments of the present disclosure are directed to methods that include delivering to a subject a nucleic acid encoding an antigen, wherein the nucleic acid is delivered via a tumor-selective vehicle or via intratumoral injection, and delivering to the subject an immune cell expressing a receptor that binds to the antigen.